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For the family physician, NSAIDs, both traditional and cyclo-oxgenase-2 inhibitors, are a valuable contri-
bution to managing arthritis and other rheumatological conditions in primary care. Yet, many of the
patients seen by the family doctor have complex comorbidities and polypharmacy issues. This review
looks at the main considerations for primary-care physicians while choosing an anti-inflammatory treat-
ment for a hypothetical patient case study. In addition to looking at the evidence for gastrointestinal
and cardiovascular risk, the concomitant use of aspirin with an NSAID is also examined. New evi-
dence for interaction between selective serotonin re-uptake inhibitors is reviewed and the interaction
between angiotensin-converting enzyme inhibitors and NSAIDs is considered. Making careful judgements
based on individual needs, medical history and comorbidities is recommended based on the evidence
reviewed.
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Introduction
‘First, do no harm’ is an axiom that has guided practitio-
ners for generations. Lately, the issue of patient safety has
been highlighted by data demonstrating the cost asso-
ciated with ‘medical harm’. It is estimated that 2% of hos-
pital admissions and $37.6 billion of American health care
spending can be attributed to medical error or medication
side effects [1]. Family physicians who treat a variety of
conditions with a large portfolio of therapies have become
increasingly sensitized to patient safety and medication
side-effect issues.
NSAIDs have been a mainstay in the arsenal of
treatments prescribed by family physicians for many
years. This class of medication provides an effective,
non-sedating, non-addictive and generally well-tolerated
treatment for patients with OA and other rheumatological
conditions. So effective and well tolerated are these
agents that they have also been used to treat other painful
conditions that are mainly managed in primary care, such
as dysmenorrhoea, migraine and post-partum pain condi-
tions [2]. With the growing range of indications and ageing
population, sales of these medications have been rising,
tripling between 1975 and 2002 in some cases [3]. With
such widespread use, safety concerns are especially
important.
The patient
The hypothetical case used in this review illustrates a
situation that may be recognized by many family practi-
tioners. OA and other musculoskeletal conditions
often occur in a population of patients with co-existing
medical conditions, which may be associated with an
increased level of gastrointestinal (GI) or cardiovascular
risk. Our case study—‘case study A’ like many others, is
elderly with a complex treatment regimen and the preser-
vation of his daily activities is an important part of his
well-being.
This patient needs a means of controlling his arthritis
pain, but his comorbid conditions need to be considered.
Notwithstanding the risks of NSAIDs in the elderly patient
with cardiac risk factors, they are often ideal medications
for those with musculoskeletal pain refractory to acetami-
nophen (paracetamol). Alternate use of opiate medica-
tions is associated with dizziness, falls, constipation,
nausea and interaction with psychotropic medications
[4, 5]. Clearly, when treating the complex older patient,
risks and benefits must be carefully weighed in order to
provide patients with an effective and well-tolerated ther-
apy that minimizes risk.
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Case study A, a hypothetical case, is an 82-year-old wid-
ower who is living independently. With a background
medical history of hypertension, Type 2 diabetes, depres-
sion, degenerative disc disease in his lower back, mild
renal failure (eGFR 55), gastro-oesophageal reflux disease
and benign prostatic hypertrophy, his medical manage-
ment is complex. His current medications include two
anti-hypertensive treatments, two oral hypoglycaemic
agents, a selective serotonin re-uptake inhibitor (SSRI),
proton pump inhibitor (PPI), NSAID, low-dose aspirin
(ASA) and selective a-blocker. Case study A enjoyed gar-
dening, daily walks in the neighbourhood and visiting his
great grandchildren. His most frequent complaint was that
of the arthritis pain that limited his activities and affected
his quality of life. After suffering a small myocardial infarc-
tion (STEMI) complicated by mild congestive heart failure,
he reported back to his family doctor for post-hospital
review. His family doctor reviewed his medications and
found that he now had three additional agents added to
his other drug treatment (b-blocker, diuretic and additional
anti-platelet medication). His NSAID had been discontin-
ued and he had been instructed to take acetaminophen
and given codeine to be taken ‘as needed for pain’. Case
study A was particularly miserable and complained that
his new medications were ruining his life. Case study A
said that his arthritis pain was ‘killing me worse than the
heart attack’. The acetaminophen provided poor pain
control—especially at night. When he took the codeine
to sleep, he was troubled by constipation. Furthermore,
it made him lightheaded, to the point that he suffered a fall
one night during his frequent visits to the toilet as a result
of his nocturia. Exasperated he asks, ‘Can’t I just have my
old arthritis pill back?’.
Patients at increased GI risk
Uppermost in the minds of clinicians both in secondary
and primary care has been the upper GI toxicity asso-
ciated with traditional NSAIDs (tNSAIDs) [6]. The risk of
upper GI bleeding is associated with risk factors, such
as age, concomitant ASA or aspirin and prednisone use,
previous GI bleeding, anti-coagulation and other chronic
medical conditions [7, 8] . In Canada, deaths associated
with GI bleeds related to NSAIDs have been reported as
being more frequent than deaths due to motor vehicle
accidents [9]. The more widespread use of ASA for cardi-
oprotection has resulted in more patients being put at risk
of GI haemorrhage.
A safety issue often overlooked is the risk of lower GI
bleeding associated with tNSAID use. Lower GI bleeding
may come from diverticular disease, colonic ulcer or ecta-
sia [10] and represents 40% of total GI bleeding [11].
Small intestinal bleeding occurring below the duodenum
is often very difficult to identify due to the lack of availabil-
ity of capsule endoscopy and for family practitioners can
involve referral to a large, possibly distant specialized
centre. It is important for practitioners to consider that
the use of PPIs is unlikely to protect the lower GI tract
from bleeding. Thus, the concomitant use of a PPI with
a tNSAID still leaves a significant amount of the GI tract at
risk of bleeding. Cyclo-oxgenase-2 (Cox-2) selective
inhibitors, with or without additional gastroprotection in
very high-risk patients, may be the best strategy for redu-
cing the risk of GI complications in those individuals, with
evidence indicating that in healthy individuals Cox-2s
result in a lower incidence of small bowel lesions than
tNSAIDs. [12, 13] More evidence in a high-risk population
would be valuable in this assessment.
GI haemorrhage related to NSAID use is often occult
[14]. Thus, treating physicians and patients cannot be
reassured by lack of abdominal symptoms. Although
bleeding may be acute and catastrophic, it is more likely
to be indolent and subtle, often resulting in a picture of
iron deficiency anaemia. Furthermore, the onset of bleed-
ing from NSAID-related GI damage can occur with even
short duration therapy [15]. Both of these factors are clin-
ically relevant—patients are still at risk despite short
course NSAID therapy, with no overt GI symptoms. GI
risk assessment should be independent of duration of
therapy or assumed tolerance.
The introduction of the selective Cox-2 inhibitors
marked an important breakthrough in patient safety. This
class of medications was found to be associated with less
GI toxicity but similar efficacy to tNSAIDs [16]. The use of
this new class of medications became widespread with
early guidelines urging their use as first line for patients
who were at high risk of GI complications from tNSAIDs
[4, 17].
Patients at increased cardiovascular risk
Initial enthusiasm for the Cox-2 inhibitors was tempered
by emerging data, which reflected increased cardiac
events in patients who were on long-term Cox-2 inhibitor
therapy [18]. Rofecoxib was the first Cox-2 reported as
causing increases in blood pressure and also cardiac
events—particularly at high dosages [19]. A study with
high-dose celecoxib also demonstrated increased cardio-
vascular incidents [20]. Later, a primarily retrospective
review suggested variable-increased cardiovascular risk
attributable to all NSAIDs—both Cox-2 selective and
non-selective [21]. This effect seemed to be dose depen-
dent and widespread throughout Cox-2 selective and
tNSAIDs.
NSAIDs and aspirin
The use of NSAIDs in patients who have risk factors for
coronary artery disease is complex. Some tNSAIDs
adversely impact the cardioprotective, anti-platelet prop-
erties of low-dose ASA by competition for Cox-1 binding
sites (Fig. 1). In a study by Catella-Lawson et al. [22],
patients with arthritis and vascular disease were given
aspirin (81mg) with either ibuprofen (400mg), paraceta-
mol (1000mg) or rofecoxib (25mg). In the first 6-day
period, the aspirin was given 2h before the ibuprofen,
paracetamol or rofecoxib and then after a wash-out
period of at least 14 days, it was given in reverse order.
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telet aggregation were inhibited nearly 100% during the
ensuing 24h. However, when ibuprofen was taken with
aspirin, Cox-1 activity was inhibited by only 53% and pla-
telet aggregation by only 2% after 24h. Ensuring ASA is
taken prior to taking an NSAID can thus overcome the
adverse effects of these NSAIDs on cardioprotective
capability associated with low-dose ASA.
However, this may not be entirely straightforward. In the
same study there were also participants who were given
multiple-dose NSAIDs: enteric-coated aspirin 2h before
ibuprofen (400mg three times a day) or 2h before a
delayed-release diclofenac 75mg two times a day). In
the ibuprofen group, platelet aggregation was inhibited
by only 10% the following morning. In contrast, in the
diclofenac group, platelet aggregation remained nearly
100% inhibited the next morning [22]. This may be
explained by the delayed absorption of the ASA due to
its enteric coating. This could have delayed absorption
and thus effect until after the ibuprofen was absorbed.
In the case of the delayed-release diclofenac, the mech-
anism of slower drug absorption allowed the ASA to be
active prior to it coming on board. Cox-2 inhibitors do not
appear to have the same effect. In the two groups taking
acetaminophen or rofecoxib in the same study, neither
drug inhibited aspirin’s anti-platelet effect when given
2h before aspirin [22].
NSAIDs and other conditions
All NSAIDs can also raise blood pressure and interfere
with the blood pressure lowering effects of certain medi-
cation classes, such as angiotensin-converting enzyme
(ACE) inhibitors [23]. The concomitant use of NSAIDs
with diuretics increases the likelihood of nephrotoxicity
as well as interfering with their blood pressure lowering
effects [24]. Electrolyte issues—particularly hyperkalae-
mia, are also associated with NSAID use [24]. NSAIDs,
both traditional and Cox-2 selective inhibitors must, there-
fore, be used with caution in all patients with renal failure.
FIG.1The effect of aspirin alone and ibuprofen plus aspirin on platelet Cox-1. (A) Demonstrates ‘Normal functioning’ of
Cox-1 receptor. (B) demonstrates how ASA irreversibly binds with the Cox 1 receptor, providing long term platelet
inhibition. (C) shows how ibuprofen similarly but temporarily blocks the receptor preventing ASA from binding and
thereby permanently inhibiting the Cox 1 receptor. Thus the cardioprotective effect of ASA may be minimized when
ibuprofen is administered prior to the ASA because the ibuprofen ‘protects’ the Cox 1 receptor from irreversible inhibition.
Reproduced with permission from Catella-Lawson et al. [22]. Copyright ! 2001 Massachusetts Medical Society.
All rights reserved.
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Richard WardCongestive heart failure can also be exacerbated by tra-
ditional and Cox-2 selective NSAIDs [25].
NSAIDs and selective serotonin
uptake inhibitors
A further emerging area of interest to family doctors is the
potential increase in GI bleeding for patients who are
taking the SSRIs. Although the data are preliminary and
retrospective, there appears to be an increase in GI bleed-
ing in patients who are on SSRIs alone, a risk which is
increased when patients are also taking NSAIDs [26, 27].
Over 26000 users of anti-depressants in North Jutland,
Denmark, were included in the study by Dalton and co-
workers [26, 27]. In individuals taking SSRIs without other
medication, the rate of upper GI bleeding was 3.6 times
more than expected (95% CI 2.7, 4.7). When combined
with either an NSAID or low-dose aspirin (GI), the risk
increased to 12.2 (95% CI 7.1, 19.5) and 5.2 (95%
CI 3.2, 8.0), respectively (Table 1).
Increased risk, but a much lower one, was found in a
retrospective study conducted in the UK with 11261
participants with upper GI bleeding and 53156 controls.
This study examined the risk of GI bleeding associated
with NSAID treatments and SSRIs when prescribed sep-
arately and together [28]. They found that concurrent pre-
scription of both drugs led to a marginally higher risk than
when one drug was prescribed [SSRI: odds ratio (OR)
2.38, 95% CI 2.08, 2.72; NSAIDs: OR 2.15, 95% CI
2.02, 2.28; SSRI + NSAID: OR 2.93, 95% CI 2.25, 3.82].
The study also found that this risk appears to be
slightly less when a selective Cox-2 inhibitor is combined
with an SSRI. This interaction with anti-inflammatory
medications is an important area for further research, as
depression is a commonly treated condition by family
physicians [28].
Conclusion
What is the right approach to case study A? Clearly, he is
at increased risk for NSAID therapy—his recent cardiac
event, renal failure, bleeding risk from medications and
underlying risk factors must be balanced by the impact
of his musculoskeletal pain on his quality of life. An initial
TABLE 1 The O/E for upper GI tract bleeding among 26005 current users of anti-depressant medication in the county of















SSRI only 17320 12760.2 55 3.6 (2.7, 4.7) 3.1
SSRI and NSAIDs only 4107 960.2 17 12.2 (7.1, 19.5) 16.3
SSRI and low-dose aspirin only 2640 1532.9 20 5.2 (3.2, 8.0) 12.4
SSRI and other drugs only 4678 1566.8 27 11.6 (7.5, 16.6) 15.8
Former use
No use of any other drug 13362 14465.6 18 1.2 (0.7, 1.9) 0.2
Non-SSRIs
Current use
Non-SSRI only 7716 8804.7 27 2.3 (1.5, 3.4) 1.8
Non-SSRI and NSAIDs only 2418 827.2 9 8.2 (3.7, 15.5) 9.6
Non-SSRI and low-dose aspirin only 927 657.7 7 4.6 (1.8, 9.4) 8.3
Non-SSRI and other drugs only 2932 1063.3 7 4.5 (1.8, 9.2) 5.1
Former use
No use of any other drug 6604 9592.4 25 2.5 (1.6, 3.6) 1.6
Other anti-depressants
Current use
Other anti-depressants only 4436 4153.7 9 1.7 (0.8, 3.1) 0.9
Other anti-depressants and NSAIDs only 1224 340.9 3 6.3 (1.3, 18.4) 7.4
Other anti-depressants and low-dose aspirin only 542 356.6 2 2.5 (0.3, 9.2) 3.4
Other anti-depressants and other drugs only 1979 726.7 5 5.2 (1.7, 12.2) 5.6
Former use
No use of any other drug 3927 5764.7 12 1.9 (1.0, 3.3) 1.0
aOther drugs include high-dose aspirin (N02B A01 and N02B A51), vitamin K antagonists (B01A A03 and B01A A04) and oral
corticosteroids (H02A B), used alone or in combination with NSAIDs (M01A) or low-dose aspirin (B01A C06 and N02B A01).
(Anatomical Therapeutic Chemical classification system codes are in parentheses.);
bthe grouping of persons is not mutually
exclusive; persons can contribute to more than one category of current use;
cthe RD is the difference between the incidence
rate of the exposed population and the incidence rate of the unexposed population (where the unexposed population equals
the relevant background population incidence). Reproduced with permission from Dalton et al. [26]. Obs: observed number of
hospitalizations for upper GI tract bleeding; O/E: observedexpected ratio; RD: rate difference.
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appropriate. Involvement with physiotherapy and occupa-
tional therapy, home care support and weight loss would
be helpful. Despite this, many patients such as case study
A would benefit from adjunct medical therapy. Before
considering the options, careful discussion with case
study A, and his family, of risks and benefits of other
therapies is important. Particularly, if NSAID therapy was
considered, careful monitoring of blood pressure, renal
function, electrolytes, haemoglobin and fluid status
would be critical. Choice of a non-tNSAID with the
lowest bleeding risk may be appropriate. Narcotic and
other alternate pain medications will almost certainly
increase risk for falls, cognitive impairment and constipa-
tion. Assisting case study A in choosing the right treat-
ment and close monitoring following the initiation
therapy will maximize the outcomes while reducing the
risks.
No solution is offered in this case because there is no
one course of treatment with a guaranteed effective out-
come: the case simply illustrates the kind of decisions that
primary-care doctors face on a regular basis.
Furthermore, any decision would be made not by the phy-
sician alone but with the patient (and his family) there to
consider the risks and benefits of the options.
With ageing patient populations, who have multiple
comorbidities and are taking increasingly more medica-
tions, patient safety issues are more important than ever
for family physicians and other primary-care providers to
consider. In the appropriate patient population, with
proper monitoring and assessment, NSAID therapy can
significantly benefit our patients’ quality of life. In selected
patients, Cox-2 selective inhibitors provide additional
safety benefit and may be considered preferentially.
However, notwithstanding their significant safety benefit
in some patient populations, they must be used in caution
in patients with renal failure, hypertension and heart
disease.
Rheumatology key messages
. Many patients who would benefit from anti-
inflammatory treatment have complex comorbid-
ities.
. Some NSAIDs affect the anti-platelet effect of aspi-
rin, whereas others appear not to.
. SSRIs plus NSAIDs may increase GI bleeding risk
but more data are needed.
Acknowledgements
Medical writing assistance was provided by Just:: Health
PR Ltd, with financial support from Pfizer Inc. A medical
writer assisted with searches of the literature and collation
of data and supported the author in the drafting of the
text. The author was fully involved in all stages of the
preparation of the manuscript.
Supplement: This paper forms part of the supple-
ment entitled ‘Balancing gastrointestinal benefitrisk in
individuals who are prescribed NSAIDs for arthritis’. This
supplement was supported by an unrestricted grant from
Pfizer Inc.
Disclosure statement: R.W. has received compensation
for speaking, program development and/or research
from Sanofi Aventis, Merck Frosst, Pfizer, Novartis,
Bristol Myer Squibb and AstraZeneca.
References
1 Kohn LT, Corrigan JM, Donaldson MS. To err is human:
building a Safer Health System. Washington, DC: National
Academy Press, 1999.
2 Todd PA, Clissold SP. Naproxen. A reappraisal of its
pharmacology, and therapeutic use in rheumatic diseases
and pain states. Drugs 1990;40:91137.
3 Hermansson M, Ekedahl A, Ranstam J, Zilling T.
Decreasing incidence of peptic ulcer complications after
the introduction of the proton pump inhibitors, a study of
the Swedish population from 19742002. BMC
Gastroenterol 2009;9:25.
4 American College of Rheumatology Subcommittee on
Osteoarthritis Guidelines. Recommendations for the
medical management of osteoarthritis of the hip and knee.
2000 Update. Arthritis Rheum 2000;43:190515.
5 Maurer PM, Bartkowski RR. Drug interactions of clinical
significance with opioid analgesics. Drug Saf 1993;8:
3048.
6 Paulus HE. FDA Arthritis Advisory Committee meeting:
serious gastrointestinal toxicity of nonsteroidal
anti-inflammatory drugs; drug-containing renal and biliary
stones; diclofenac and carprofen approved. Arthritis
Rheum 1988;31:14501.
7 Lanas A, Garcı ´a-Rodrı ´guez LA, Arroyo MT et al. Risk of
upper gastrointestinal ulcer bleeding associated with
selective cyclo-oxygenase-2 inhibitors, traditional
non-aspirin non-steroidal anti-inflammatory drugs, aspirin
and combinations. Gut 2006;55:17318.
8P e ´rez Gutthann S, Garcia ´ Rodrı ´guez LA, Raiford DS.
Individual nonsteroidal anti-inflammatory drugs and other
risk factors for upper gastrointestinal bleeding and perfo-
ration. Epidemiology 1997;8:1824.
9 Hunt RH, Barkun AN, Baron D et al. Recommendations for
the appropriate use of anti-inflammatory drugs in the era
of coxibs: defining the role of gastroprotective agents.
Can J Gastroenterol 2002;16:23140.
10 Wilcox CM, Clarke WS. Association of nonsteroidal anti
inflammatory drugs with outcome in upper and lower
gastrointestinal bleeding. Dig Dis Sci 1997;42:9859.
11 Laine L, Connors LG, Reicin A et al. Serious lower gas-
trointestinal clinical events with nonselective NSAID or
coxib use. Gastroenterology 2003;124:28892.
12 Goldstein JL, Eisen GM, Lewis B, Gralnek IM, Zlotnick S,
Fort JG. Video capsule endoscopy to prospectively
assess small bowel injury with celecoxib, naproxen plus
omeprazole, and placebo. Clin Gastroenterol Hepatol
2005;3:13341.
13 Goldstein JL, Eisen GM, Lewis B et al. Small bowel
mucosal injury is reduced in healthy subjects treated with
celecoxib compared with ibuprofen plus omeprazole, as
assessed by video capsule endoscopy. Aliment
Pharmacol Ther 2007;25:121122.
ii22 www.rheumatology.oxfordjournals.org
Richard Ward14 Lanas A, Scarpignato C. Microbial flora in NSAID-induced
intestinal damage: a role for antibiotics? Digestion 2006;73
(Suppl. 1):13650.
15 Herna ´ndez-Dias S, Garcia-Rodrı ´guez LA. Association
between nonsteroidal anti-inflammatory drugs and upper
gastrointestinal tract bleeding/perforation. An overview of
epidemiological studies published in the 1990s. Arch
Intern Med 2000;160:20939.
16 Rostom A, Muir K, Dube ´ C et al. Gastrointestinal safety of
cyclooxygenase-2 inhibitors: a Cochrane Collaboration
systematic review. Clin Gastroenterol Hepatol 2007;5:
81828.
17 American College of Rheumatology Subcommittee on
Rheumatoid Arthritis Guidelines. Guidelines for the
Management of Rheumatoid Arthritis. 2002 Update.
Arthritis Rheum 2002;46:32846.
18 Bresalier RS, Sandler RS, Quan H et al. Cardiovascular
events associated with rofecoxib in a colorectal
adenoma chemoprevention trial. N Engl J Med 2005;352:
1092102.
19 Bombardier C, Laine L, Reicin A et al. Comparison of
upper gastrointestinal toxicity of rofecoxib and naproxen
in patients with rheumatoid arthritis. N Engl J Med 2000;
343:15208.
20 Solomon SD, McMurray JV, Pfeffer MA et al.
Cardiovascular risk associated with celecoxib in a clinical
trial for colorectal adenoma prevention. N Engl J Med
2005;352:107180.
21 McGettigan P, Henry D. Cardiovascular risk and inhibition
of cyclooxygenase: a systematic review of the
observational studies of selective and nonselective
inhibitors of cyclooxygenase 2. JAMA 2006;296:163344.
22 Catella-Lawson F, Reilly MP, Kapoor SC et al.
Cyclooxygenase inhibitors and the antiplatelet effects
of aspirin. N Eng J Med 2001;345:180917.
23 Stys T, Lawson WE, Smaldone GC, Stys A. Does aspirin
attenuate the beneficial effects of angiotensin-converting
enzyme inhibition in heart failure? Arch Intern Med 2000;
160:140913.
24 Whelton A. Nephrotoxicity of nonsteroidal
anti-inflammatory drugs: physiologic foundations and
clinical implications. Am J Med 1999;106 (Suppl. 5B):
13S24.
25 Gislason HG, Rasmussen JN, Abildstrom SZ et al.
Increased mortality and cardiovascular morbidity
associated with use of nonsteroidal anti-inflammatory
drugs in chronic heart failure. Arch Intern Med 2009;169:
1419.
26 Dalton SO, Sørensen HT, Johansen C. SSRIs and upper
gastrointestinal bleeding: what is known and how should it
influence prescribing? CNS Drugs 2006;20:14351.
27 Dalton SO, Johansson C, Mellemkjaer L et al. Use of
selective serotonin re-uptake inhibitors and risk of upper
gastrointestinal tract bleeding. Arch Intern Med 2003;163:
5964.
28 Tata LJ, Fortun PJ, Hubbard RB et al. Does concurrent
prescription of selective serotonin reuptake inhibitors and
non-steroidal anti-inflammatory drugs substantially
increase the risk of upper gastrointestinal bleeding?
Aliment Pharmacol Ther 2005;22:17581.
www.rheumatology.oxfordjournals.org ii23
The family physician and GI benefitrisk